Characteristics | JIA with OSA, n = 35 | JIA without OSA, n = 33 | p |
---|---|---|---|
Disease subtype | 0.15 | ||
Oligoarticular | 6 (17.1) | 13 (39.4) | |
Extended oligoarticular | 7 (20.0) | 6 (18.2) | |
Polyarticular RF–negative | 12 (34.3) | 10 (30.3) | |
Polyarticular RF–positive | 0 (0) | 1 (3.0) | |
Systemic | 6 (17.1) | 1 (3.0) | |
Enthesitis-related | 2 (5.7) | 2 (6.1) | |
Psoriatic | 2 (5.7) | 0 (0) | |
JIA disease activity | 0.30 | ||
Active | 16 (45.7) | 11 (33.3) | |
Inactive | 19 (54.3) | 22 (66.7) | |
Physician’s global rating, 0–10 | 1.03 ± 1.5 | 0.75 ± 1.5 | 0.76 |
Disease duration, mos | 38.8 ± 28.7 | 36.6 ± 28.8 | 0.75 |
Active joint count | 1.74 ± 3.8 | 1.4 + 5.3 | 0.91 |
Pain | |||
Evening pain | 0.86 ± 1.4 | 0.55 ± 1.3 | 0.15 |
Evening joint count | 0.51 | ||
0 | 25 (71.4) | 27 (81.8) | |
1 | 5 (14.3) | 4 (12.1) | |
2 | 3 (8.6) | 2 (6) | |
3 | 2 (5.7) | 0 (0) | |
Medications | |||
DMARD | 14 (40.0) | 18 (54.5) | |
Sulfasalazine | 4 (11.4) | 1 (3.0) | |
Biologics | 10 (28.6) | 6 (18.2) | |
NSAID | 16 (45.7) | 11 (33.3) | |
Corticosteroids | 1 (2.9) | 2 (6.1) | |
Other, vitamins | 19 (54.3) | 20 (60.6) | |
No medication | 4 (11.4) | 6 (18.2) |
JIA: juvenile idiopathic arthritis; OSA: obstructive sleep apnea; RF: rheumatoid factor; DMARD: disease-modifying antirheumatic drugs; NSAID: nonsteroidal antiinflammatory drugs.